| 陈英 詹晓蓉 殷微微 贾睿博.2 型糖尿病患者早期使用胰高血糖素样受体激动剂[J].,2015,15(11):2195-2197 |
| 2 型糖尿病患者早期使用胰高血糖素样受体激动剂 |
| Early Use of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1 RAs) in Type 2 Diabetes |
| |
| DOI： |
| 中文关键词: 2型糖尿病 胰高血糖素样肽1类似物 艾塞那肽 利拉鲁肽 安全性 有效性 |
| 英文关键词: Type 2 diabetes Glicagon like peptide-1 Exenatide Lireglutide Efficacy Safety |
| 基金项目:黑龙江省教育厅基金项目（12511233） |
|
| 摘要点击次数: 698 |
| 全文下载次数: 749 |
| 中文摘要: |
| 糖尿病目前已成为继心血管疾病和肿瘤之后的第三位主要非传染性疾病，其中90%为2 型糖尿病患者。胰高血糖素样肽-1
类似物（GLP-I类似物）作为一种新型的降糖药物，具有降低体重、降低收缩压、改善胰岛细胞功能，已成为2 型糖尿病治疗的新热
点。艾塞那肽和利拉鲁肽作为肠促胰素激素，与人体内天然GLP-1 保持了高度同源性（97%）。近几年来受到人们广泛关注。本综
述针对2 型糖尿病患者早期使用胰岛素样受体激动剂艾塞那肽和利拉鲁肽的安全性和有效性进行评估。 |
| 英文摘要: |
| Diabetes has become,after cardiovascular disease and cancer, the third major non-communicable diseases, of which
90%of type 2 diabetes. Glicagon like peptide-1(GLP-1), was a new antidiabetic drug, which had some effect on decreasing body weight,
depressing systolic pressure and improving islet cell function, which has become the treatment of type 2 diabetes new hot spot. Exenatede
and liraglutide as incretin hormones, and the body of natural GLP-1to maintain a high degree of homology(97%). In recent year, Glicagon
like peptide-1 get much more attention. Here, we review available evidence fromclinical trials regarding the efficacy and safety of GLP-1
RAs. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
